Counterfeit Medications

Counterfeit Medications

1. Definition & terminology — the WHO SSFFC → "Substandard and Falsified (SF)" framework

• Counterfeit (falsified) medications are a major category of compromised medical product that, together with substandard and adulterated drugs, incorrect or unsafe clinical use, overdose and accidental exposure, undermine drug safety even after a drug has cleared marketing approval (G&G 14e Ch.8, p.145).
  • G&G frames postmarketing safety as governed by both the drug (PK, PD, selectivity, known/unknown ADRs and drug quality) and the use of the drug; "drug quality" is the node under which counterfeit, substandard and adulterated products sit (G&G 14e Ch.8, p.146, Figure 8–1).
• WHO terminology has evolved deliberately. The historical umbrella term was SSFFC — Substandard, Spurious, Falsely-labelled, Falsified and Counterfeit medical products. At the Seventieth World Health Assembly (WHA70, May 2017), Member States replaced SSFFC with the simpler "Substandard and Falsified (SF)" medical products, and agreed three working definitions [WHO] (WHA70, 2017).
  • The word "counterfeit" was deliberately set aside in the public-health lexicon because it had become entangled with intellectual-property / trademark law (a counterfeit is, strictly, a trademark infringement), which is a commercial concern distinct from the public-health concern of a product that fails to protect or treat the patient. Using "falsified" keeps the focus on patient harm, not brand protection [WHO] (WHA70, 2017).
  • In common usage and in older Indian statute, "counterfeit," "spurious" and "fake" are used loosely for what WHO now calls falsified; the postgraduate answer should map the colloquial term onto the precise WHO/legal category [WHO] (WHA70, 2017).
• WHO category 1 — Substandard medical products (also called "out of specification"): authorised medical products that fail to meet either their quality standards or their specifications, or both — i.e. genuine, registered products from registered manufacturers that are out of spec (sub-potent, super-potent, contaminated, wrong dissolution, degraded) usually from poor manufacturing practice or inadequate quality control [WHO] (WHA70, 2017; WHO fact-sheet).
• WHO category 2 — Unregistered / unlicensed medical products: products that have not undergone evaluation and/or approval by the national or regional regulatory authority for the market in which they are marketed, distributed or used. They may meet quality standards or not, but bypass the regulatory gate (e.g. diversion, unapproved imports) [WHO] (WHA70, 2017).
• WHO category 3 — Falsified medical products (the public-health successor to "counterfeit"): products that deliberately / fraudulently misrepresent their identity, composition or source [WHO] (WHA70, 2017; WHO fact-sheet).
  • Identity misrepresentation = false name, ingredients, strength, dosage form, packaging, labelling, expiry. Composition = wrong/no/insufficient active pharmaceutical ingredient (API), or wrong ingredients (including toxic substitutes such as diethylene glycol — the same toxic solvent that killed >100 people in the 1937 US sulfanilamide elixir disaster that prompted the 1938 Food, Drug and Cosmetic Act, and the recurring toxin in paediatric cough-syrup poisoning incidents) (mechanism of harm: G&G 14e Ch.8, p.145 on the sulfanilamide–DEG disaster); source = false manufacturer or country of origin [WHO] (WHA70, 2017).
  • Falsification is defined by intent to deceive, made/repackaged/sold by criminals for financial gain — this is the dividing line from substandard products, which arise from quality failure, not fraud [WHO] (WHO fact-sheet).
• Key conceptual distinction for exams — substandard (genuine but out-of-spec, a quality-systems / GMP failure) vs falsified (fraudulent, a criminal act). A falsified product may also be substandard (most are, since the falsifier has no quality system), but the legal and regulatory response differs: substandard → recall, GMP enforcement, manufacturing-licence action; falsified → criminal prosecution [WHO] (WHA70, 2017).

1.1 Mapping WHO categories onto Indian statutory terms

• Indian law predates and does not use the WHO "falsified/substandard" vocabulary; instead the Drugs and Cosmetics Act, 1940 (D&C Act) uses "spurious," "adulterated," "misbranded" and "not of standard quality (NSQ)" [D&C Act] (§17, §17A, §17B).
• Approximate mapping: WHO falsified ≈ Indian spurious (§17B); WHO substandard ≈ Indian adulterated / not of standard quality (§17A and NSQ under §16); misbranded (§17) covers false/misleading labelling that overlaps both [D&C Act] (§17, §17A, §17B).